Klaus Hollmig

6.1k citations

48 papers · 3.7k indexed · 2 hit papers · h-index 21

Co-authors: Bart Barlogie Frits van Rhee Mauricio Pineda‐Roman Guido Tricot John D. Shaughnessy Maurizio Zangari John Crowley Elias Anaissie
Topics: Multiple Myeloma Research and Treatments (44 papers)Protein Degradation and Inhibitors (14 papers)Cancer Treatment and Pharmacology (12 papers)
Cited by: Hematology Oncology Molecular Biology
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States Germany

In The Last Decade

Klaus Hollmig

48 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The molecular classification of multiple myeloma

2006 783 citations Fenghuang Zhan, Yongsheng Huang et al. Blood profile →
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 532 citations Bart Barlogie, Guido Tricot et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Klaus Hollmig

Since Specialization

Citations

This map shows the geographic impact of Klaus Hollmig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Hollmig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Hollmig more than expected).

Fields of papers citing papers by Klaus Hollmig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Hollmig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Hollmig. The network helps show where Klaus Hollmig may publish in the future.

Co-authorship network of co-authors of Klaus Hollmig

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Hollmig. A scholar is included among the top collaborators of Klaus Hollmig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Hollmig. Klaus Hollmig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols 2009 ·Blood ·Antje Hoering,John Crowley,John D. Shaughnessy,Klaus Hollmig,Yazan Alsayed,Jackie Szymonifka,Sarah Waheed,Bijay Nair,Frits van Rhee,Elias Anaissie,Bart Barlogie	63
2	Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma 2008 ·Cancer ·Bart Barlogie,Elias Anaissie,Jeffrey Haessler,Fritz Van Rhee,Mauricio Pineda‐Roman,Klaus Hollmig,Yazan Alsayed,Joshua Epstein,John D. Shaughnessy,John Crowley	90
3	Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 2008 ·Journal of Clinical Oncology ·Bart Barlogie,E. Anaissie,Frits van Rhee,John D. Shaughnessy,J. Haessler,Mauricio Pineda‐Roman,Klaus Hollmig,Joshua Epstein,John J. Crowley	5
4	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling 2007 ·Clinical Cancer Research ·Jeffrey Haessler,John D. Shaughnessy,Fenghuang Zhan,John Crowley,Joshua Epstein,Frits van Rhee,Elias Anaissie,Mauricio Pineda‐Roman,Maurizio Zangari,Klaus Hollmig,Abid Mohiuddin,Yazan Alsayed,Antje Hoering,Guido Tricot,Bart Barlogie	75
5	Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics 2007 ·British Journal of Haematology ·John D. Shaughnessy,Jeffrey Haessler,Frits van Rhee,Elias Anaissie,Mauricio Pineda‐Roman,Michele Cottler‐Fox,Klaus Hollmig,Maurizio Zangari,Abid Mohiuddin,Yazan Alsayed,Monica Grazziutti,Joshua Epstein,John Crowley,Bart Barlogie	38
6	Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications 2007 ·Journal of Clinical Oncology ·Ronald C. Walker,Bart Barlogie,Jeffrey Haessler,Guido Tricot,Elias Anaissie,John D. Shaughnessy,Joshua Epstein,Rudy Van Hemert,Erdem Eren,Antje Hoering,John Crowley,Ernest J. Ferris,Klaus Hollmig,Frits van Rhee,Maurizio Zangari,Mauricio Pineda‐Roman,Abid Mohiuddin,Shmuel Yaccoby,Jeffrey R. Sawyer,Edgardo J. Angtuaco	283
7	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 2007 ·British Journal of Haematology ·Bart Barlogie,Elias Anaissie,Frits van Rhee,Jeffrey Haessler,Klaus Hollmig,Mauricio Pineda‐Roman,Michele Cottler‐Fox,Abid Mohiuddin,Yazan Alsayed,Guido Tricot,Vanessa Bolejack,Maurizio Zangari,Joshua Epstein,Nathan Petty,(unknown),Bonnie Jenkins,(unknown),Ellen Sullivan,John Crowley,John D. Shaughnessy	245
8	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease 2006 ·British Journal of Haematology ·Mauricio Pineda‐Roman,Vanessa Bolejack,(unknown),Elias Anaissie,Frits van Rhee,Maurizio Zangari,(unknown),Klaus Hollmig,John D. Shaughnessy,Joshua Epstein,Somashekar G. Krishna,John Crowley,Bart Barlogie	51
9	Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myelomabreakdown → 2006 ·New England Journal of Medicine ·Bart Barlogie,Guido Tricot,Elias Anaissie,John D. Shaughnessy,Erik Rasmussen,Frits van Rhee,Athanasios Fassas,Maurizio Zangari,Klaus Hollmig,Mauricio Pineda‐Roman,Choon Lee,Giampaolo Talamo,Raymond Thertulien,Elias Kiwan,Somashekar G. Krishna,M. Fox,John Crowley	532
10	Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma 2006 ·Clinical Lymphoma & Myeloma ·Bart Barlogie,Maurizio Zangari,Vanessa Bolejack,Klaus Hollmig,Elias Anaissie,Frits van Rhee,Mauricio Pineda‐Roman,Abid Mohiuddin,John Crowley,Guido Tricot	10
11	Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis 2006 ·Blood ·Fenghuang Zhan,Bart Barlogie,(unknown),Yongsheng Huang,D. R. Williams,Klaus Hollmig,Mauricio Pineda‐Roman,Guido Tricot,Frits van Rhee,Maurizio Zangari,Madhav V. Dhodapkar,John D. Shaughnessy	287
12	An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups. 2006 ·Blood ·John D. Shaughnessy,Jeffrey Haessler,(unknown),Yongsheng Huang,Fenghuang Zhan,Jeffrey R. Sawyer,Elias Anaissie,Frits van Rhee,Guido Tricot,Joshua Epstein,Maurizio Zangari,Mauricio Pineda‐Roman,Klaus Hollmig,John Crowley,Bart Barlogie	6
13	A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis. 2006 ·Blood ·Fenghuang Zhan,Bart Barlogie,(unknown),Yongsheng Huang,Klaus Hollmig,Mauricio Pineda‐Roman,Guido Tricot,Frits van Rhee,Maurizio Zangari,Madhav V. Dhodapkar,John D. Shaughnessy	12
14	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival. 2005 ·Blood ·Guido Tricot,Erik Rasmussen,Elias Anaissie,Frits van Rhee,Maurizio Zangari,Klaus Hollmig,Lisa Jackson,Joshua Epstein,John D. Shaughnessy,John Crowley,Bart Barlogie	7
15	Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant 2004 ·Bone Marrow Transplantation ·CK Lee,Maurizio Zangari,Bart Barlogie,Athanasios Fassas,Frits van Rhee,Raymond Thertulien,Giampaolo Talamo,Firas Muwalla,E. Anaissie,Klaus Hollmig,Guido Tricot	83
16	Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS). 2004 ·Blood ·Guido Tricot,John Crowley,(unknown),(unknown),Athanasios Fassas,Maurizio Zangari,Raymond Thertulien,Elias Anaissie,Frits van Rhee,(unknown),Klaus Hollmig,Bart Barlogie	2
17	Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients 2003 ·Blood ·E. Anaissie,Joth Jacobson,Athanasios Fassas,Maurizio Zangari,Raymond Thertulien,(unknown),(unknown),Guido Tricot,(unknown),(unknown),Klaus Hollmig,Bart Barlogie	1
18	Down-regulation of IL-2 receptor α (CD25) characterizes human γδ-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12 2002 ·Cancer Immunology Immunotherapy ·(unknown),Klaus Hollmig,Richard D. Lopez	15
19	Acquired factor VIII inhibitors in nonhemophilic patients 1997 ·Annals of Hematology ·D. Söhngen,Christof Specker,D. R. Bach,(unknown),M. Burk,C. Aul,Guido Kobbe,A. Heyll,Klaus Hollmig,Wolfgang Schneider	59
20	Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia 1997 ·Leukemia Research ·Carlo Aul,Norbert Gattermann,Ulrich Germing,T Südhoff,Klaus Hollmig,A. Heyll	11

About Klaus Hollmig

Klaus Hollmig is a scholar working on Hematology, Oncology and Molecular Biology, having authored 48 papers that have together received 3.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (14 papers) and Cancer Treatment and Pharmacology (12 papers). The work is most often cited by research in Hematology (3.2k citations), Oncology (1.6k citations) and Molecular Biology (2.7k citations). Klaus Hollmig has collaborated with scholars based in United States and Germany. Frequent co-authors include Bart Barlogie, Frits van Rhee, Mauricio Pineda‐Roman, Guido Tricot, John D. Shaughnessy, Maurizio Zangari, John Crowley, Elias Anaissie, Joshua Epstein and Fenghuang Zhan. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact